Alpha 1 Antitrypsin Deficiency (AATD) Financial Cost
"Alpha-1 Antitrypsin Deficiency (AATD) Financial Cost" provides an in-depth analysis of the financial burdens associated with Alpha-1 Antitrypsin Deficiency (AATD), referencing 14 unique research studies. These studies cover various aspects of medical expenses, including augmentation therapy, hospitalization, emergency care, outpatient care, and the long-term financial impact on patients and families. The book offers valuable insights into the economic challenges faced by AATD patients and their families, helping them make informed decisions about treatment options, insurance coverage, and resource allocation.

The book contributes to the development of healthcare strategies by highlighting the cost-effectiveness of various treatment options and identifying areas where financial support is needed. It brings innovative ideas and research by examining emerging treatments, such as gene therapy and small molecule therapies, and their economic impact. Additionally, the book offers strategies for reducing healthcare costs and improving the overall quality of life for AATD patients. This comprehensive approach makes it a valuable resource for anyone interested in the financial aspects of healthcare and the management of Alpha-1 Antitrypsin Deficiency.
1146268792
Alpha 1 Antitrypsin Deficiency (AATD) Financial Cost
"Alpha-1 Antitrypsin Deficiency (AATD) Financial Cost" provides an in-depth analysis of the financial burdens associated with Alpha-1 Antitrypsin Deficiency (AATD), referencing 14 unique research studies. These studies cover various aspects of medical expenses, including augmentation therapy, hospitalization, emergency care, outpatient care, and the long-term financial impact on patients and families. The book offers valuable insights into the economic challenges faced by AATD patients and their families, helping them make informed decisions about treatment options, insurance coverage, and resource allocation.

The book contributes to the development of healthcare strategies by highlighting the cost-effectiveness of various treatment options and identifying areas where financial support is needed. It brings innovative ideas and research by examining emerging treatments, such as gene therapy and small molecule therapies, and their economic impact. Additionally, the book offers strategies for reducing healthcare costs and improving the overall quality of life for AATD patients. This comprehensive approach makes it a valuable resource for anyone interested in the financial aspects of healthcare and the management of Alpha-1 Antitrypsin Deficiency.
3.99 In Stock
Alpha 1 Antitrypsin Deficiency (AATD) Financial Cost

Alpha 1 Antitrypsin Deficiency (AATD) Financial Cost

by Azhar Ul Haque Sario
Alpha 1 Antitrypsin Deficiency (AATD) Financial Cost

Alpha 1 Antitrypsin Deficiency (AATD) Financial Cost

by Azhar Ul Haque Sario

eBook

$3.99 

Available on Compatible NOOK devices, the free NOOK App and in My Digital Library.
WANT A NOOK?  Explore Now

Related collections and offers

LEND ME® See Details

Overview

"Alpha-1 Antitrypsin Deficiency (AATD) Financial Cost" provides an in-depth analysis of the financial burdens associated with Alpha-1 Antitrypsin Deficiency (AATD), referencing 14 unique research studies. These studies cover various aspects of medical expenses, including augmentation therapy, hospitalization, emergency care, outpatient care, and the long-term financial impact on patients and families. The book offers valuable insights into the economic challenges faced by AATD patients and their families, helping them make informed decisions about treatment options, insurance coverage, and resource allocation.

The book contributes to the development of healthcare strategies by highlighting the cost-effectiveness of various treatment options and identifying areas where financial support is needed. It brings innovative ideas and research by examining emerging treatments, such as gene therapy and small molecule therapies, and their economic impact. Additionally, the book offers strategies for reducing healthcare costs and improving the overall quality of life for AATD patients. This comprehensive approach makes it a valuable resource for anyone interested in the financial aspects of healthcare and the management of Alpha-1 Antitrypsin Deficiency.

Product Details

BN ID: 2940185808092
Publisher: Azhar ul Haque Sario and Tammy Aikens Co.
Publication date: 09/13/2024
Sold by: Barnes & Noble
Format: eBook
File size: 275 KB

About the Author

I am bestselling author. I have proven technical skills (Google certifications) to deliver insightful books with ten years of business experience.
From the B&N Reads Blog

Customer Reviews